Click Here to return To Results

 

Trial of Fingolimod Versus Interferon Beta-1a in Pediatric Multiple Sclerosis NEJM 379:1017-1027, Chitnis, T.,et al, 2018 See this aricle in Pubmed Article Abstract Among pediatric patients with relapsing multiple sclerosis, fingolimod was associated with a lower rate of relapse and less accumulation of lesions on MRI over a 2-year period than interferon beta-1a but was associated with a higher rate of serious adverse events. Longer studies are required to determine the durability and safety of fingolimod in pediatric multiple sclerosis.

Related Tags

(click to filter results - removes previous filter) adverse drug reaction children complications fingolimod immunotherapy MRI,abnormal multiple sclerosis multiple sclerosis,children multiple sclerosis,relapsing multiple sclerosis,treatment of safety treatment of neurologic disorder

Click Here to return To Results